Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (10,848,000)	$ (4,177,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,559,000	4,562,000
Share-based compensation	5,565,000	18,627,000
Payment-in-kind “PIK” interest	4,371,000	0
Gain on troubled debt restructuring	0	(30,311,000)
Net accretion of investments	(181,000)	(34,000)
Loss on disposal of property, equipment, and capitalized software	87,000	245,000
Other, net	493,000	2,000
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(5,122,000)	(850,000)
ACO REACH performance year receivable	(373,271,000)	(530,749,000)
Other assets	(120,000)	(3,507,000)
Medical cost payable	(15,495,000)	(13,263,000)
Risk adjustment payable	(4,996,000)	(11,224,000)
Accounts payable and other liabilities	(4,920,000)	(5,612,000)
Unearned revenue	0	(11,000)
Warrant liability	(2,649,000)	(2,072,000)
ACO Reach performance year obligation	382,478,000	529,657,000
Net cash used in operating activities	(21,049,000)	(48,717,000)
Cash flows from investing activities:
Purchases of investments	(1,195,000)	0
Proceeds from sales, paydowns, and maturities of investments	4,258,000	2,321,000
Purchases of property and equipment	(1,026,000)	(64,000)
Proceeds from sale of business, net	61,139,000	196,130,000
Net cash provided by investing activities	63,176,000	198,387,000
Cash flows from financing activities:
Repayments of short-term borrowings	(1,000,000)	(273,636,000)
Distributions to noncontrolling interest holders	(1,702,000)	(1,884,000)
Net cash used in financing activities	(2,702,000)	(275,520,000)
Net increase (decrease) in cash and cash equivalents	39,425,000	(125,850,000)
Cash and cash equivalents of total operations – beginning of year	185,405,000	375,280,000
Cash and cash equivalents of total operations – end of period	224,830,000	249,430,000
Supplemental disclosures of cash flow information:
Changes in unrealized gain on available-for-sale securities in OCI	$ 0	$ 18,000